Biomedical subjects

P Litwak

Publications and source records attributed to P Litwak.

At least 37 records · Page 2Linked to original sources

PubMed1988

In vivo evaluations of a new thromboresistant polyurethane for artificial heart blood pumps.

To reduce the risk of thromboembolic complications in prosthetic blood pumps, we have developed a new segmented polyurethane elastomer. This material is unique because its mechanical properties for long-term durability and surface properties for biocompatibility have been separated and developed in two distinct materials. Improved thromboresistance is then obtained by a 1% concentration of a new polymeric surface-modifying additive blended with the base polyurethane before fabrication of the blood pump. To evaluate this material in vivo, we performed 10 implants, in calves, of the Pierce-Donachy prosthetic ventricle with blood-pumping sacs and cannulas fabricated from the new surface-modifying additive copolymer blend (Thoratec's BPS-215M). In four control implants the blood sacs and cannulas were fabricated from Ethicon's Biomer segmented polyurethane, which is the present clinical standard for most artificial hearts and circulatory support devices. The blood pumps were connected from the apex of the left ventricle to the descending aorta in male Holstein calves weighing 82 to 108 kg and were driven pneumatically in the full-to-empty mode with flows averaging 5 to 6 L/min. Each calf was medicated with aspirin and dipyridamole throughout the study period and was electively put to death after 4 weeks for evaluation of explanted blood sacs and for examination of the kidneys for infarction. All 10 explanted blood sacs made with the surface-modifying additive copolymer blend were shiny and completely free of thrombus. Three of the four explanted Biomer blood sacs showed visible red thrombus, and all four showed small areas of white thrombus. The average surface area of the Biomer blood sacs covered with thrombus was 45 +/- 32 mm2. Use of a semiquantitative scale to assess renal infarction demonstrated that nine of 10 animals with a surface-modifying additive copolymer blend blood sac had infarction less severe than the mean infarct score of the animals with a Biomer sac. The surface-modifying additive copolymer blend has excellent mechanical and physical properties necessary for use in artificial heart blood pumps. From these experiments, we conclude that the surface-modified polyurethane blend is superior to Biomer polyurethane in blood compatibility and in freedom from thromboembolic risk. This material is now approved by the Food and Drug Administration for investigational device exemption studies in the Pierce-Donachy prosthetic ventricle.

Animals↗

PubMed1979

Platelet turnover studies associated with left ventricular assist device (LVAD) implantation.

Calves given LVADs have been studied to determine changes in platelet turnover induced by the device and modified by time and anticoagulants. Passivation with time occurs but is surprisingly incomplete even one month later and despite coumadin, aspirin and dipyridamole. Without these drugs, enhanced platelet turnover and local thrombus formation on the device is exaggerated. Sequential platelet turnover studies may be useful to quantitate, monitor and/or predict thromboembolic events.

Animals↗

PubMed1979

A volume sensor for a pneumatically driven LVAD.

The volume sensor has proven to be a valuable tool in the operation and characterization of our pneumatically driven LVAD. It compensates for the decoupling between driver and LVAD that occurs in pneumatically actuated LVADs due to gas compressibility. Uses to which we have put the volume sensor represent only a small fraction of the potential applications. Additional uses contemplated include: Use as an alternate or backup for the R-wave detection network currently used to achieve synchronization with the natural heart. This could be done by starting the LVAD ejection phase when the filling flow rate drops below a given threshold, indicating that the left ventricle has finished filling the LVAD. Use for feedback for closed loop control of plate motion. Such control could reduce actuation delays without overdriving the LVAD. Use as a diagnostic tool to aid in the study of the LVAD and its interaction with the cardiovascular system. When used in conjunction with information on left ventricular, aortic, and drive pressures, it is possible to determine the resistance, inertia and compliant characteristics of the major elements of the LVAD and the vascular system to which it is joined.

Assisted Circulation↗

PubMed1978

Lumbar spondylectomy in the subhuman primate.

Removal of the 2nd or 3rd lumbar vertebrae (or both) has been accomplished in the subhuman primate (Macaca mulatta). Variations between this animal and the dog in posture, vertebral column anatomy, and spinal cord blood supply made no apparent difference in the results when compared with those in previous experiments. All macaques were able to clinb and to use their hind legs in a normal manner within 3 days after surgical operation. Once hair had regrown over the surgical incision, persons not familiar with the animals were not able to identify the animals that had undergone surgical operation. If a single vertebra was removed, use of spinous process and a single vertebral body plate was sufficient to stabilize the vertebral column. Except for 1 rhesus macaque whose spinous process plates were removed 20 days after the operation, vertebral columns of macaques (n = 3) that underwent single spondylectomy healed in nearly normal alignment. With the removal of 2 lumbar vertebrae, the previously described stabilization procedure was not sufficient to prevent kyphotic deformity of the vertebral column. Spinous process plates from 1 macaque were removed after 64 days. However, all these macaques (n = 3) could climb and use their legs as well as others in the colony.

Animals↗

PubMed1976

Aggressive pharmacologic and surgical treatment of spinal cord injuries in dogs and cats.

Aggressive pharmacologic and surgical treatment of spinal cord injuries in 22 dogs and 3 cats resulted in a recovery rate of 44% of all 25 animals. Excluding 5 animals that were euthanatized at surgery because of visualized cord transection and 5 that died during surgery because of secondary lesions, the recovery rate was 73%. This is compared with a recovery rate of 39% (7/18) for animals treated with more conservative methods at the same institution during an earlier period. Of the 7 animals without spinal cord transection and treated within 4 hours of injury, all recovered, pointing to the merits of early surgical intervention.

Aminocaproates↗

PubMed1976

Surgical preparation of miniature swine for atherosclerosis research.

A 2-stage surgical procedure for chronic intestinal, vascular, and lymphatic sampling in miniature swine is described. Cannulas were placed in the jejunum and ileum, followed by a 2nd implantation of indwelling catheters in the portal and hepatic veins, caudal vena cava, abdominal aorta, and cisterna chyli. The techniques used proved that miniature swine can be surgically adapted to meet experimental requirements.

Animals↗

PubMed1975

A vascular catheter-implanting device.

A catheter-implanting device (CID) was developed to aid in the placement of vascular catheters in blood vessels located deep in the body cavities, with minimal vascular damage or blood loss.

Animals↗

PubMedDate not supplied

Dynamic systemic vascular resistance in a sheep supported with a Nimbus AxiPump.

Changes in systemic vascular resistance (SVR) in response to diminished pulse perfusion were analyzed over a dynamic range of flow conditions. An axial flow LVAD (Nimbus AxiPump, Rancho Cordova, CA) was implanted in a sheep for 28 days, during which time SVR was determined over several conditions of posture and excitability. Total arterial resistance (TR) was calculated dynamically as an index of SVR by analysis of pump flow in diastole, and systemic pressure estimated from the characteristic pressure-flow-speed relation of the AxiPump. TR was evaluated over a range of flow rates, including maximum flow--for which the pressures and flows were essentially nonpulsatile. Throughout the course of support, and independent of pulsatility, TR dropped when the sheep stood and was significantly lower than that in the sitting position (P < 0.01). Response to excitement followed the same trend: TR was significantly higher during agitation than during normal temper (P < 0.01). In spite of changes in pulse pressure and flow rate, SVR changes occurred according to expected physiologic responses for pulsatile perfusion. Because pump flow and pressure are sensitive to afterload, the results of these studies suggest that pump speed control must compensate for changes in SVR to maintain acceptable perfusion.

Animals↗

PubMedDate not supplied

An intraventricular axial flow blood pump integrated with a bearing purge system.

The future development of implantable axial flow blood pumps must address two major issues: mechanically induced hemolysis and shaft seal reliability. The recent revisions to our miniature intraventricular axial flow left ventricular assist device (LVAD) were aimed particularly at addressing these concerns. To improve hemocompatibility, a new impeller has been designed according to the following criteria: 1) gradual pressure rise along the blade chord; 2) minimized local fluid acceleration to prevent cavitation; 3) minimum surface roughness; and 4) radius edges. Subsequent in vitro hemolysis tests conducted with bovine and ovine blood have demonstrated very low hemolysis (normalized index of hemolysis = 0.0051 +/- 0.0047 g/100 L) with this new impeller design. To address the need for a reliable seal, we have developed a purged seal system consisting of a miniature lip seal and ceramic pressure groove journal bearing that also acts as a purge pump. Several spiral grooves formed on the bearing surface provide viscous pumping of the purge fluid, generating more than 3,000 mmHg at 10,000 rpm. This purge flow flushes the lip seal and prevents blood backflow into the bearing. We have found this purge pump to offer several advantages because it is simple, compact, durable, does not require separate actuation, and offers a wide range of flow, depending upon the groove design. In vivo animal tests demonstrated the potential of the purged seal system.

Animals↗

PubMedDate not supplied

Acute in vivo studies of the Pittsburgh intravenous membrane oxygenator.

The efficacy of an innovative intravenous membrane oxygenator (IMO) was tested acutely (6-8 hrs) in seven calves. The IMO prototypes consisted of a central polyurethane balloon within a bundle of hollow fibers with a membrane surface area of 0.14 m2. The IMO devices were inserted through the external jugular vein into the inferior vena cava of anesthetized calves (68.9 +/- 2.3 kg). Rhythmic balloon pulsation (60-120 bpm) was controlled with an intra-aortic balloon pump console. Oxygen sweep gas was delivered through the device at 3.0 L/min. Gas concentrations were monitored continuously by mass spectroscopy. The principal results were as follows: 1) oxygen and carbon dioxide exchange ranged from 125 to 150 ml/min/m2 and 150 to 200 ml/min/m2, respectively; 2) there was at least a 30-50% augmentation of gas exchange with balloon pulsation; 3) maximum exchange occurred with 60-90 bpm balloon pulsations; and 4) hemodynamic parameters remained unchanged. There were no device related complications, and the feasibility of insertion of the device by a cervical cut-down was established. These acute in vivo experiments show that the Pittsburgh IMO device can exchange oxygen and carbon dioxide gases in vivo at levels consistent with this current prototype design, and that intravenous balloon pulsation significantly enhances gas exchange without causing any end-organ damage.

Adult↗

PubMedDate not supplied

Progress on development of the Nimbus-University of Pittsburgh axial flow left ventricular assist system.

Nimbus Inc. (Rancho Cordova, CA) and the University of Pittsburgh have completed the second year of development of a totally implanted axial flow blood pump under the National Institutes of Health Innovative Ventricular Assist System Program. The focus this year has been on completing pump hydraulic development and addressing the development of the other key system components. Having demonstrated satisfactory pump hydraulic and biocompatibility performance, pump development has focused on design features that improve pump manufacturability. A controller featuring full redundancy has been designed and is in the breadboard test phase. Initial printed circuit layout of this circuit has shown it to be appropriately sized at 5 x 6 cm to be compatible with implantation. A completely implantable system requires the use of a transcutaneous energy transformer system (TETS) and a diagnostic telemetry system. The TETS power circuitry has been redesigned incorporating an improved, more reliable operating topography. A telemetry circuit is undergoing characterization testing. Closed loop speed control algorithms are being tested in vitro and in vivo with good success. Eleven in vivo tests were conducted with durations from 1 to 195 days. Endurance pumps have passed the 6 month interval with minimal bearing wear. All aspects of the program continue to function under formal quality assurance.

Heart-Assist Devices↗

PubMedDate not supplied

Induction of ventricular collapse by an axial flow blood pump.

An important consideration for clinical application of rotary blood pump based ventricular assist is the avoidance of ventricular collapse due to excessive operating speed. Because healthy animals do not typically demonstrate this phenomenon, it is difficult to evaluate control algorithms for avoiding suction in vivo. An acute hemodynamic study was thus conducted to determine the conditions under which suction could be induced. A 70 kg calf was implanted with an axial flow assist device (Nimbus/UoP IVAS; Nimbus Inc., Rancho Cordova, CA) cannulated from the left ventricular apex to ascending aorta. On initiation of pump operation, several vasoactive interventions were performed to alter preload, afterload, and contractility of the left ventricle. Initially, dobutamine increased contractility and heart rate ([HR] = 139; baseline = 70), but ventricular collapse was not achievable, even at the maximal pump speed of 15,000 rpm. Norepinephrine decreased HR (HR = 60), increased contractility, and increased systemic vascular resistance ([SVR] = 24; baseline = 15), resulting in ventricular collapse at a pump speed of 14,000 rpm. Isoproterenol (beta agonist) increased HR (HR = 103) and decreased SVR (SVR = 12), but ventricular collapse was not achieved. Inferior vena cava occlusion reduced preload, and ventricular collapse was achieved at speeds as low as 11,000 rpm. Esmolol (beta1 antagonist) decreased HR (HR = 55) and contractility, and ventricular collapse was achieved at 11,500 rpm. Episodes of ventricular collapse were characterized initially by the pump output exceeding the venous return and the aortic valve remaining closed throughout the cardiac cycle. If continued, the mitral valve would remain open throughout the cardiac cycle. Using these unique states of the mitral and aortic valves, the onset of ventricular collapse could reliably be identified. It is hoped that the ability to detect the onset of ventricular collapse, rather than the event itself, will assist in the development and the evaluation of control algorithms for rotary ventricular assist devices.

Adrenergic alpha-Agonists↗

PubMedDate not supplied

Chronic animal health assessment during axial ventricular assistance: importance of hemorheologic parameters.

Chronic testing of the Nimbus/UOP Axial Flow Pump was performed on 22 calves for periods of implantation ranging from 27 to 226 days (average, 74 days). The following parameters were measured: plasma free hemoglobin, blood and plasma viscosity, erythrocyte deformability and mechanical fragility, oxygen delivery index (ODI), blood cell counts, hematocrit, hemoglobin, blood urea nitrogen, creatinine, bilirubin, total protein, fibrinogen, and plasma osmolality. Most of the above parameters were stable during the full course of support. Compared with baseline, statistically significant differences during the entire period of implantation were only found in: hematocrit (p<0.001), hemoglobin (p<0.005), red blood cell (RBC) count (p<0.001), and whole blood viscosity (p<0.01). Plasma viscosity and ODI were mostly stable during the period of implantation. In some animals, an acute increase in fibrinogen concentration, plasma and blood viscosity, and a decrease in ODI were found to be early signs of the onset of infection. A small (10%) decrease in deformability of RBCs was found during the first 2 weeks after implantation. This alteration in RBC deformability was highly correlated (r = 0.793) with changes in total plasma protein concentration that fell more than 15% (p<0.001) during the same period. Mechanical fragility of RBCs was found to be slightly increased after implantation. Plasma free hemoglobin remained close to baseline level (p>0.2). After the first 2 weeks of the postoperative period, pump performing parameters for all animals were consistent and stable. In general, the Nimbus/UOP Axial Flow Pump demonstrated basic reliability and biocompatibility and did not produce significant alterations in the mechanical properties of blood or animal health status. The pump provided adequate hemodynamics and was well tolerated by the experimental animal for periods as long as 7.5 months. Monitoring rheologic parameters of blood is very helpful for evaluation of health during heart-assist device application.

Animals↗

PubMedDate not supplied

Relationship of blood pressure and pump flow in an implantable centrifugal blood pump during hypertension.

The purpose of this study was to evaluate the real time relationship between pump flow and pump differential pressure (D-P) during experimentally induced hypertension (HT). Two calves (80 and 68 kg) were implanted with the EVA-HEART centrifugal blood pump (SunMedical Technology Research Corp., Nagano, Japan) under general anesthesia. Blood pressure (BP) in diastole was increased to 100 mm Hg by norepinephrine to simulate HT. Pump flow, D-P, ECG, and BP were measured at pump speeds of 1,800, 2,100, and 2,300 rpm. All data were separated into systole and diastole, and pump flow during HT was compared with normotensive (NT) conditions at respective pump speeds. Diastolic BP was increased to 99.3+/-4.1 mm Hg from 66.5+/-4.4 mm Hg (p<0.01). D-P in systole was under 40 mm Hg (range of change was 10 to 40 mm Hg) even during HT. During NT, the average systolic pump flow volume was 60% of the total pump flow. However, during HT, the average systolic pump flow was 100% of total pump flow volume, although the pump flow volume in systole during HT decreased (33.1+/-5.7 vs. 25.9+/-4.0 ml/systole, p<0.01). In diastole, the average flow volume through the pump was 19.6+/-6.9 ml/diastole during NT and -2.2+/-11.1 ml/diastole during HT (p<0.01). The change in pump flow volume due to HT, in diastole, was greater than the change in pump flow in systole at each pump speed (p<0.001). This study suggests that the decrease of mean pump flow during HT is mainly due to the decrease of the diastolic pump flow and, to a much lesser degree, systolic pump flow.

Animals↗

PubMedDate not supplied

HeartMate III: pump design for a centrifugal LVAD with a magnetically levitated rotor.

A long-term, compact left ventricular assist device (LVAD), the HeartMate III, has been designed and fabricated, featuring a centrifugal pump with a magnetically levitated rotor. The pump has been optimized by in vitro testing to achieve a design point of 7 L/min against 135 mm Hg at high hydrodynamic efficiency (30%) and to be capable of up to 10 L/min under such a load. Furthermore, the pump has demonstrated no mechanical failures, low hemolysis (4-10 mg/dl plasma free Hb), and low thrombogenicity during six (40, 27, 59, 42, 27, and 49-day) in vivo bovine studies.

Animals↗

PubMedDate not supplied

Thoratec VAD system as a bridge to heart transplantation.

As of October 1988 the Thoratec ventricular assist device system was used in 72 heart transplant candidates at 20 medical centers in five countries. All patients were in imminent risk of dying before donor heart procurement, with a mean cardiac index of 1.6 +/- 0.5 L/min/m2 and a pulmonary capillary wedge pressure of 27 +/- 8 mm Hg, in spite of maximal medical therapy. The ventricular assist device system consists of a prosthetic ventricle (Pierce-Donachy design) with a 65 ml pumping chamber, made of Thoratec's BPS-215M polyurethane, appropriate cannulae for atrial or ventricular inflow and for arterial outflow connections, and a pneumatic drive console. The devices can be used for partial or complete support of the pulmonary and systemic circulations. Fifty-eight (81%) of the 72 patients received biventricular devices and 14 received support only on the left side of the heart. Average flow rate was 5.0 +/- 0.7 L/min on the left side and 4.3 +/- 0.7 on the right. Fifty-four patients (75%) recovered sufficiently to undergo heart transplantation after a median of 4.4 days (mean, 14.3 days; range, 8 hours to 81 days), and 45 of them have been discharged from the hospital (83% early posttransplant survival and 63% overall survival from implant to discharge). Of 14 patients supported for more than 30 days, 11 underwent heart transplantation, and nine were discharged alive. The actuarial 1- and 2-year posttransplant survival rates are 78% and 75%. We conclude that these heterotopic prosthetic devices provide an effective method of maintaining blood flow to vital organs until a donor heart can be procured.(ABSTRACT TRUNCATED AT 250 WORDS)

Actuarial Analysis↗

PubMedDate not supplied

Bridge to cardiac transplantation: successful use of prosthetic biventricular support in a patient awaiting a donor heart.

A 33-year-old man with dilated cardiomyopathy was successfully "bridged" to cardiac transplantation, with the use of left and right prosthetic ventricles. The prostheses supported the pulmonary and systemic circulations for 87 h, at which time they were removed and orthotopic transplantation was performed. Heart transplantation is the only viable long-term therapy for end-stage dilated cardiomyopathy. In the case of sudden decompensation in a patient who requires cardiac transplantation, if a suitable allograft is not immediately available, a system of prosthetic ventricles can be used to provide hemodynamic support until a donor organ is located. In addition, the use of a prosthetic ventricle or ventricles does not preclude the possibility of recovery of ventricular function, an option that is removed if a total artificial heart is used.

Adult↗

PubMedDate not supplied

In vivo evaluation of an extracorporeal pediatric centrifugal blood pump.

This paper summarizes the authors' in vivo experience in evaluating a miniature centrifugal blood pump designed for pediatric/neonatal ventricular support. Left ventricular bypass was accomplished in two adult sheep and five juvenile lambs (5.5-80.0 kg) via either central (left ventricle to carotid artery) or peripheral (jugular vein to carotid artery) cannulation. Animals were weaned from mechanical ventilation and continuously monitored. Hemodynamic parameters remained within a normal range over the duration of the bypass. Two of five lambs were electively killed at 8, and 76 hours; the remaining three lambs died from respiratory complications at 33, 44, and 156 hours. There were no mechanical complications, and blood seal integrity was confirmed beyond 6 days. The pump speed was maintained at 3,000-4,500 rpm with pump flow rates between 0.4-1.5 L/min. Average plasma free hemoglobin was below 20 mg/dl in the five lamb experiments. Renal, hepatic, and hematologic indices also remained within physiologic ranges. Histopathologic analyses of major organs revealed renal cortical infarctions in two of five lambs. Examination of the pump surfaces after explant indicated small areas of thrombus in the housing adjacent to the outflow ports in two experiments. These encouraging results support further testing and refinement of this miniature centrifugal pump.

Animals↗